ATC Group: A03AB05 Propantheline

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of A03AB05 in the ATC hierarchy

Level
Code
Title
1
Alimentary tract and metabolism
2
Drugs for functional gastrointestinal disorders
3
DRUGS FOR FUNCTIONAL BOWEL DISORDERS
4
Synthetic anticholinergics, quaternary ammonium compounds
5
A03AB05
Propantheline

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route
Amount
ORAL - Oral
60 mg
PAREN - Parenteral
60 mg

Active ingredients in A03AB05

Active Ingredient
Description

Propantheline inhibits parasympathetic activity by blocking the action of the neurohormone, acetylcholine, on the neuroeffector cell. This blocking action of propantheline is instrumental in reducing gastric acid secretion and gastrointestinal motor activity.

Medicines in this ATC group

Drug
Countries

Australia New Zealand United Kingdom

Related product monographs

Title
Type
Country
Summary of Product Characteristics (SPC)
UK